Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents
作者： Thomas J Lynch , Alex A Adjei , Paul A Bunn Jr , Tim G Eisen , Jeffrey Engelman
DOI: 10.1158/1078-0432.CCR-06-1005
关键词:
摘要: The Third Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was convened Cambridge, Massachusetts September 23 to 24, 2005 discuss ongoing research into significance epidermal growth factor receptor (EGFR) pathway biology non–small cell lung cancer
aacrjournals.org
elsevier.com
utsystem.edu参考文章(3)
Mark R. Green, Targeting Targeted Therapy The New England Journal of Medicine. ,vol. 350, pp. 2191- 2193 ,(2004) , 10.1056/NEJME048101
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149